What is the actual efficacy of Apremilast (Otelac)? Patient feedback and clinical observations

Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor mainly used to treat moderate to severe plaque psoriasis and psoriatic arthritis (PsA). It inhibits PDE4 and increases intracellular cyclic adenosine monophosphate (cAMP) levels, thereby regulating the expression of inflammatory cytokines, reducing the levels of pro-inflammatory factors (such as TNF-α, IL-23), and increasing the activity of anti-inflammatory factors (such as IL-10). This unique mechanism of action makes apremilast an important option in the systemic treatment of psoriasis and psoriatic arthritis.

From clinical observation, the efficacy of apremilast is manifested in relieving skin symptoms, improving arthritis symptoms, and improving patients' quality of life. Multiple Phase III clinical trials (such as the PALACE and ESTEEM studies) have shown that after 12 to 16 weeks of continuous use, approximately 30% to 40% of psoriasis patients can achieve the efficacy of PASI-75 (skin lesion area and severity index reduced by 75%). The symptoms of joint pain, swelling and morning stiffness in arthritis patients have also been significantly improved. Compared with traditional immunosuppressants, apremilast has the advantages of convenient oral administration, no need for injections, and no need for routine laboratory monitoring, making patient compliance higher.

In terms of patient feedback, most patients said that apremilast can significantly improve their quality of life and ability to perform daily activities. After skin symptoms are relieved, itching, pain and rash area are reduced, which can help reduce psychological stress and social anxiety. People with psoriatic arthritis report significant improvements in joint range of motion, duration of morning stiffness, and finger and knee joint pain, and are able to perform daily tasks and sports more smoothly. These patient feedbacks are consistent with clinical quantitative indicators, showing the reliability of the efficacy of apremilast in practical applications.
However, some patients respond slowly or incompletely to apremilast. Clinical data shows that some patients need to continue taking the drug for more than 16 weeks to observe significant improvement. At the same time, the efficacy is affected by individual differences, disease duration and comorbid diseases. Common adverse reactions include mild to moderate diarrhea, nausea, headache and weight loss, but most symptoms can be self-limited or relieved by supportive treatment and do not affect long-term medication. Physicians often individualize dosage or treatment regimens based on patient response and tolerability to optimize efficacy.
Based on comprehensive clinical observations and patient feedback, apremilast has the characteristics of high safety, good tolerance, and long-term application of sustainable control of inflammation in patients with moderate to severe plaque psoriasis and psoriatic arthritis. Although there are certain individual differences in efficacy, overall, it can significantly improve skin and joint symptoms and improve patients' quality of life. It is an oral drug option worthy of consideration in current systemic treatment. At the same time, patients should insist on taking medications regularly during medication and maintain close communication with their doctors in order to adjust the treatment plan in a timely manner and achieve the best therapeutic effect.
Reference: https://www.drugs.com/